# Scipher Medicine Financial Model

AI-powered blood test platform that predicts which autoimmune patients will not respond to biologic therapies, routing them to better drugs from day one.

- Canonical: https://finamodel.com/startups/scipher-medicine
- Excel download: https://finamodel.com/startup-models/scipher-medicine.xlsx
- Category: Biotech/Pharma
- Model type: SaaS ARR / Valuation
- Funding round: Series D

- Founded: 2022
- Geography: US (payer/PBM contracts, rheumatologist network implied).
- Customer: B2B2C

## About the company

Scipher Medicine’s Prism blood tests predict whether autoimmune patients will not respond to anti-TNF biologics before treatment begins. Its spectra AI platform identifies patient-specific disease signatures, while the AIMS clinico-genomic data lake grows with each ordered test and creates a separate pharma-data opportunity.

Diagnostics revenue comes from payer and PBM reimbursement for provider-ordered tests, while pharma partners buy data and analysis for discovery and development. The company had 23 payer or PBM contracts covering 21 million patients. Reimbursement price, test COGS, milestone structure, and royalty terms are not disclosed.

PrismRA reports 90% prediction accuracy and launched first, with PrismIBD planned next. Scipher had raised $117 million, accumulated more than 10,000 patients in its data lake, and achieved an 85% repeat-ordering rate among providers. The model should forecast tests, coverage, providers, lab cost, data deals, and evidence generation.

## What's included

- 5-year monthly revenue build with stage-appropriate growth assumptions
- Full P&L, headcount plan, and operating-expense schedule
- Cash-flow statement, runway, and burn-rate tracking
- Valuation via exit multiple with a DCF cross-check
- Returns analysis with MOIC and IRR
- Unit economics including CAC, LTV, payback, and cohort retention

## Product & value proposition

- **Prism® test suite**: Blood-based molecular signature tests predicting non-response to anti-TNF biologics before treatment begins. One test architecture, multiple disease indications.
- **spectra® platform**: Underlying network biology AI/ML engine; superimposes whole-blood RNAseq data onto protein interaction networks to identify patient-specific disease signatures and drug-response biomarkers.
- **AIMS® data lake**: Clinico-genomic database of tested patients, fed by every test ordered; monetized separately via pharma partnerships.
- Launched indications:
  - **PrismRA®** (Rheumatoid Arthritis): Launched 2020/2021. 23-biomarker panel. 90% prediction accuracy; patient outcomes improve 40%; potential savings $7B.
  - **PrismIBD®** (Ulcerative Colitis/IBD): 2022 launch planned. 90%+ prediction accuracy; outcomes improve 30%; potential savings $3B.
  - **PrismMS** (Multiple Sclerosis): In development.

## Market

- Total autoimmune disease TAM: **$42B**.
- By indication:
  - RA: 5M patients, **$25B TAM**.
  - IBD: 2M patients, **$10B TAM**.
  - MS: 1.3M patients, **$7B TAM**.
- Addressable drug class: anti-TNFs - **$33B annual global sales**, world's largest drug class; **65% of patients do not respond**.
- Total ineffective drug spend in complex diseases: **$552B/year** globally; vs. oncology where only $78B ineffective vs. $26B effective.
- SAM/SOM not broken out in deck.
- Growth rates not stated; market share trajectory implied by provider adoption curve (slide 13).

## Revenue model

**Stream 1 - Diagnostics (testing revenue)**
- Payers and PBMs reimburse for Prism® tests ordered by rheumatologists/gastroenterologists.
- Channel: Direct to payer/PBM (B2B contracts), providers order the test.
- 23 signed payer/PBM contracts; accessible to **21 million patients** at time of deck. Named: Top-3 PBM, Top-5 BCBS plan, Largest health plan GPO, Largest Managed Medicaid plan.
- Test price / reimbursement rate: **Not in deck**.

**Stream 2 - Data monetization (pharma partnerships)**
- Pharma/biotech companies pay for access to AIMS® data lake insights and spectra® platform analysis for preclinical target ID and drug development.
- Deal value signed to date: **$0.5B**.
- Deal value under negotiation: **$1B**.
- Deal structure (milestones, royalties, upfront): **Not in deck**.

## Traction & metrics

- **$117M raised** to date.
- **5 Prism® tests** launched in 5 years, starting with PrismRA in 2021.
- **10k+ patients** in clinico-genomic data lake at time of summary slide; data lake growth chart shows: 11,000 (2021) → 36,000 (2022) → 66,000 (2023) → 102,000 (2024).
- **~530 cumulative ordering providers** (rheumatologists) by Dec of first year = 15% of all US rheumatologists.
- **85% repeat ordering rate** among providers who ordered at least once.
- **23 signed payer/PBM contracts**.
- **21 million patients** with current payer coverage access.
- **$0.5B in pharma data deal value signed**; **$1B under negotiation**.
- Revenue figures ($): **Not in deck**.
- Cost / COGS per test: **Not in deck**.

## Unit economics

- **Cost per responding patient - Standard of Care**: $172,961.
- **Cost per responding patient - With PrismRA®**: $112,000 (38% reduction).
- **ACR50 response rate - Standard of Care**: 11.1%; **with PrismRA®**: 39.6% (257% improvement; 4x more patients respond).
- Test ASP/reimbursement: **Not in deck**.
- CAC (provider or payer side): **Not in deck**.
- Gross margin: **Not in deck**.
- LTV: **Not in deck**.

## Competition / moat

- First-mover in autoimmune diagnostics; slide 23 draws explicit parallel to oncology precision medicine leaders (Foundation Medicine, Guardant, GRAIL, Tempus, Exact Sciences) - Scipher positioned as the sole equivalent in autoimmune.
- Moat sources stated or implied:
  - 10+ years of research; RNA-based (PM 2.0 vs. DNA-based PM 1.0).
  - Proprietary AIMS® clinico-genomic data lake - scale (102k patients by 2024) creates compounding barrier.
  - Network biology AI platform (spectra®) - not replicable without matching data volume.
  - Payer/PBM contract network (23 contracts, 21M covered lives) creates switching cost.
- No named direct competitors in deck.

## Team & funding ask / use of funds

- **120+ employees**.
- Leadership (slide 21): CEO Alif Saleh (two exits); CFO John Strumbos ($560M raised); CTO Slava Akmaev PhD (AI/biomarker pioneer); CCO Chip Parkinson ($1B+ revenue); CMO Sam Asgarian MD (former CMO Thrive, $1B+ exit); GC Sam Davis ($1.8B SPAC).
- Advisors: 18th US Surgeon General; former Global President Inflammation & Immunology Pfizer; former SVP Immunology Janssen.
- Investors: UnitedHealth Group / Optum, Khosla Ventures, aMoon, Echo Health Ventures, Northpond Ventures.
- **$117M raised to date**.
- Round size being raised: **Not in deck**.
- Use of funds: **Not in deck**.

---

## Recommended financial model

- **Archetype + why**: Dual-revenue diagnostics + data partnership model. Stream 1 is a volume-based diagnostic revenue model (tests × ASP × payer mix reimbursement rate), similar to lab/diagnostics companies (Myriad, Guardant). Stream 2 is a milestone/partnership revenue model (upfront + milestone payments from pharma collaborations). These are structurally distinct and should be modeled as separate P&L segments with a consolidated summary - a 3-statement model with segment revenue build.

- **Forecast horizon & granularity**: 5-year annual (Year 1–5), with Year 1 monthly for cash burn visibility given pre-profitability stage. Two revenue segments modeled separately.

- **Key drivers & assumptions**:

  *Diagnostics segment*
  - Total addressable patients per indication (RA: 5M, IBD: 2M, MS: 1.3M)
  - % eligible for testing (biologic-naive patients starting anti-TNF)
  - Provider penetration rate (15% of rheumatologists at Month 12)
  - Provider ramp curve
  - Tests per provider per year
  - Repeat order rate: 85%
  - ASP / reimbursement per test
  - Payer coverage ramp (currently 21M lives / 23 contracts);
  - COGS per test (lab processing, reagents, phlebotomy)

  *Data monetization segment*
  - Signed deal value: $0.5B
  - Pipeline deal value: $1B
  - Revenue recognition:
  - New deals per year
  - Data lake patients: 11k→36k→66k→102k (2021–2024);

  *Cost structure*
  - R&D (test development, platform):
  - S&M (provider/payer sales force):
  - G&A:
  - Headcount: 120+;
  - Capex (lab equipment):

- **Scenarios (Base / Bull / Bear - which variables flex)**:
  - **Base**: Provider penetration ramps to 30% of rheumatologists by Year 3; ASP $1,800; 2 new pharma deals/year; IBD launches on schedule 2022.
  - **Bull**: Provider penetration hits 40%+ by Year 3; ASP $2,200 (stronger payer pricing); MS launches Year 3; 3–4 new pharma deals/year; data lake hits 200k patients by 2025.
  - **Bear**: Provider penetration stalls at 20% (reimbursement friction); ASP pressure to $1,200 (payer pushback); pharma deal pipeline closes slowly (1/year); MS delayed.

- **Required sheets / outputs**:
  1. Assumptions - all drivers above, toggleable by scenario
  2. Diagnostics Revenue Build - by indication (RA / IBD / MS), provider count × tests × ASP
  3. Data Partnership Revenue Build - deal pipeline, recognition schedule
  4. P&L (consolidated + segmented) - gross margin by segment, EBITDA, net income
  5. Headcount & Opex Build
  6. Balance Sheet (simplified)
  7. Cash Flow Statement - cash burn / runway (key for growth-stage)
  8. Summary / Dashboard - KPIs: tests ordered, active providers, covered lives, data lake size, revenue by segment, EBITDA margin, cash runway

## Frequently asked questions

### Is the Scipher Medicine financial model free?

Yes. The Scipher Medicine model is a free Excel download with live formulas.

### Can I change the assumptions?

Yes. The workbook is editable and its live formulas recalculate when assumptions change.